Literature DB >> 12088844

Acute and long-term effects of the 5-HT2 receptor antagonist ritanserin on EEG power spectra, motor activity, and sleep: changes at the light-dark phase shift.

Sandor Kantor1, Rita Jakus, Robert Bodizs, Peter Halasz, Gyorgy Bagdy.   

Abstract

Parallel effects of a single injection of the 5-HT(2) receptor antagonist ritanserin on EEG power spectra, sleep and motor activity were measured for a 20-h period in freely moving Sprague-Dawley rats. Ritanserin (0.3 mg/kg, i.p.), administered at light onset (passive phase), caused an immediate transient increase in the EEG power density in the low frequency range (0.25-6 Hz, mainly delta activity) and a depression in the high frequency range (27-30 Hz) accompanied by a decrease in vigilance and light slow wave sleep (SWS-1), intermediate stage of sleep and increase in deep slow wave sleep (SWS-2) compared to control treatment. All these effects were over 8 h after the injection. Twelve hours after the injection, at dark onset (active phase), there was a marked increase in vigilance and motor activity and decrease in SWS-1 and spindle frequency activity in the control animals, but all these changes were diminished by ritanserin treatment. These effects resulted in a significant relative increase in the intermediate band (peak: 12-15 Hz) of the EEG power spectra and thus, a relative increase in thalamo-cortical synchronization caused by ritanserin at dark onset. Because ritanserin is a selective 5-HT(2) receptor antagonist, we conclude that under physiological conditions serotonin increases EEG desynchronization and produces an increase in vigilance level and motor activity by tonic activation of 5-HT(2) receptors. This regulatory mechanism plays an important role in the waking process, and the appearances of its effects in the light and dark phase are markedly different.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12088844     DOI: 10.1016/s0006-8993(02)02698-7

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

1.  Differential adaptation of REM sleep latency, intermediate stage and theta power effects of escitalopram after chronic treatment.

Authors:  Szilvia Vas; Zita Kátai; Diána Kostyalik; Dorottya Pap; Eszter Molnár; Péter Petschner; Lajos Kalmár; György Bagdy
Journal:  J Neural Transm (Vienna)       Date:  2012-06-24       Impact factor: 3.575

2.  A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers.

Authors:  Louise M Paterson; Sue J Wilson; David J Nutt; Peter H Hutson; Magnus Ivarsson
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

3.  Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF-06372865.

Authors:  Sarah A Nickolls; Rachel Gurrell; Guido van Amerongen; Juha Kammonen; Lishuang Cao; Adam R Brown; Clara Stead; Andy Mead; Christine Watson; Cathleen Hsu; Robert M Owen; Andy Pike; Rebecca L Fish; Laigao Chen; Ruolun Qiu; Evan D Morris; Gang Feng; Mark Whitlock; Donal Gorman; Joop van Gerven; David S Reynolds; Pinky Dua; Richard P Butt
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

4.  Neuroelectric responses of sportsmen and sedentaries under cognitive stress.

Authors:  Onur Bayazit; Gamze Üngür
Journal:  Cogn Neurodyn       Date:  2018-01-23       Impact factor: 5.082

5.  Chronic escitalopram treatment caused dissociative adaptation in serotonin (5-HT) 2C receptor antagonist-induced effects in REM sleep, wake and theta wave activity.

Authors:  Diána Kostyalik; Zita Kátai; Szilvia Vas; Dorottya Pap; Péter Petschner; Eszter Molnár; István Gyertyán; Lajos Kalmár; László Tóthfalusi; Gyorgy Bagdy
Journal:  Exp Brain Res       Date:  2014-01-07       Impact factor: 1.972

6.  A hidden Markov model to assess drug-induced sleep fragmentation in the telemetered rat.

Authors:  C Diack; O Ackaert; B A Ploeger; P H van der Graaf; R Gurrell; M Ivarsson; D Fairman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-09-10       Impact factor: 2.745

7.  Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA.

Authors:  Brigitta Balogh; Eszter Molnar; Rita Jakus; Linda Quate; Henry J Olverman; Paul A T Kelly; Sandor Kantor; Gyorgy Bagdy
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

8.  Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505.

Authors:  Sandor Kantor; Rita Jakus; Brigitta Balogh; Anita Benko; Gyorgy Bagdy
Journal:  Br J Pharmacol       Date:  2004-07-20       Impact factor: 8.739

9.  Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats.

Authors:  Stephen R Morairty; Linda Hedley; Judith Flores; Renee Martin; Thomas S Kilduff
Journal:  Sleep       Date:  2008-01       Impact factor: 5.849

10.  Screening for candidate gene regions in narcolepsy using a microsatellite based approach and pooled DNA.

Authors:  Stefan Wieczorek; Peter Jagiello; Larissa Arning; Norbert Dahmen; Joerg T Epplen
Journal:  J Mol Med (Berl)       Date:  2004-08-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.